Table 2.

Clinical sequelae following administration of extended-release buprenorphine (BUP-XR)

	Test group and incidence of clinical signs
Clinical sign	Low dose males	High dose males	Low dose females	High dose females
Forelimb lameness	No clinical signs	2 of 6	2 of 6	1 of 6
Ear-tag inflammation			2 of 6	1 of 6
Urinary sedimentation		5 of 6	3 of 6	4 of 6
Vaginal discharge			1 of 6	1 of 6
Abdominal mass and wound		1 of 6
Injection-site dermatoses		1 of 6
Paw dermatoses				1 of 6
Forelimb scab or alopecia				3 of 6

BUP-XR dosages = 0.65 and 1.3 mg/kg body weight in low dose group and high dose group, respectively.